Publications and presentations
Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD. Blood (Nov 2020) 136 (Supplement 1): 6–7.
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Adrian Newland and Vickie McDonald. Immunotherapy. 10.2217/imt-2020-0215. Oct 2020.
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Haematologica. 2017 Aug;102(8):1342-1351
Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Quentin Hill, Robert Stamps, Edwin Massey, John Grainger, Drew Provan and Anita Hill, Brit J Haemat, 2017, 177, 208-220
Comparison of the effects of the TPO receptor agonist, Romiplostim, in patients with ITP < 1yr versus > 1yr. DJ Kuter, AC Newland, BH Chong, F Rodegheiro, MT Romero, I Pabinger, Y Chen, B Metha, M Eisen. ASH 2017; BLOOD 2017, 130, 1055
Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Eur J Haematol. 2016 Oct;97(4):321-30
July 2020 - Virtual presentation with Haemostasis Connect - Current perspectives on the treatment of primary chronic ITP in adults: CME-accredited, independent, virtual symposium
Poster presentation, 2019, European Haematology Association (EHA) - Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP effect outcomes? Data from the UK ITP registry. Todd S et al
Poster presentation, 2018, EHA - Epidemiology and Management of Primary Immune Thrombocytopenia: Real world data from the UK ITP Registry. Zaidi A et al
Oral presentation, 2018, British Society for Haematology (BSH) - Comparison of standard- and low-dose rituximab in Primary Immune Thrombocytopenia (ITP): data from the UK ITP registry. C Gracie et al